Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina

被引:6
作者
Bazemore, Taylor C. [1 ]
Nanna, Michael G. [2 ]
Rao, Sunil V. [2 ]
机构
[1] Duke Univ, Dept Internal Med, Med Ctr, Box 3182, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Div Cardiol, Dept Internal Med, Durham, NC 27710 USA
关键词
P2Y12; inhibitor; Clopidogrel; Preloading; Cardiac catheterization; Acute coronary syndrome; ELEVATION MYOCARDIAL-INFARCTION; ARTERY-BYPASS SURGERY; ACUITY ACUTE CATHETERIZATION; 300 MG CLOPIDOGREL; PLATELET INHIBITION; ANTIPLATELET THERAPY; P2Y(12) INHIBITORS; CLINICAL-OUTCOMES; PRETREATMENT; INTERVENTION;
D O I
10.1007/s11239-017-1529-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment with P2Y12 inhibitors is an integral part of the standard of care for patients undergoing percutaneous coronary intervention. However, the most appropriate timing for P2Y12 inhibitor administration remains unclear, and the value of "preloading" with P2Y12 inhibitors prior to cardiac catheterization is controversial. While pre-catheterization treatment with P2Y12 inhibitors is performed with the goal of decreasing adverse cardiovascular events, this potential benefit must be weighed against the increased risk of bleeding complications and operative delay if coronary artery bypass graft surgery is indicated. A number of studies have been conducted to evaluate the utility of preloading with P2Y12 inhibitors prior to cardiac catheterization for varying indications including stable angina and acute coronary syndrome (ACS). In this article, we review the literature and discuss the advantages and disadvantages of the preloading strategy. Several individual studies offer inconclusive and even conflicting findings. However, when taken in sum, these studies allow for several conclusions about the utility of P2Y12 inhibitor pretreatment. The existing literature demonstrate that preloading is associated with some degree of reduction in adverse ischemic events, although this benefit comes with an increased risk of bleeding complications. The appropriateness of preloading therefore varies based on the indication for catheterization, likely justified in patients with ACS but unlikely to benefit patients with stable angina.
引用
收藏
页码:303 / 315
页数:13
相关论文
共 50 条
  • [31] P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis
    Yan, Longhui
    Zhou, Yan
    Yu, Zhangjie
    Xuan, Mengmei
    Xu, Buyun
    Peng, Fang
    MEDICINE, 2022, 101 (27) : E29824
  • [32] P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes
    Alexopoulos, Dimitrios
    Varlamos, Charalampos
    Mpahara, Aikaterini
    Lianos, Ioannis
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (10) : 717 - 727
  • [33] Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes
    Joshi, Rajiv R.
    Hossain, Rashed
    Morton, Allison C.
    Ecob, Rosemary
    Judge, Heather M.
    Wales, Clare
    Walker, Jemma V.
    Karunakaran, Arun
    Storey, Robert F.
    PLATELETS, 2014, 25 (06) : 416 - 422
  • [34] Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis
    Carrillo-Aleman, Luna
    Marin, Francisco
    Rivera-Caravaca, Jose M.
    Vicente-Ibarra, Nuria
    Candela-Sanchez, Elena
    Esteve-Pastor, Maria A.
    Lozano, Teresa
    Sandin-Rollan, Miriam
    Pernias-Escrig, Vicente
    Macias, Manuel
    Quintana-Giner, Miriam
    Veliz, Andrea
    Orenes-Pinero, Esteban
    Martinez-Martinez, Juan G.
    Ruiz-Nodar, Juan M.
    CLINICAL DRUG INVESTIGATION, 2019, 39 (03) : 275 - 283
  • [35] P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
    Galli, Mattia
    Laudani, Claudio
    Occhipinti, Giovanni
    Spagnolo, Marco
    Gragnano, Felice
    D'Amario, Domenico
    Navarese, Eliano Pio
    Mehran, Roxana
    Valgimigli, Marco
    Capodanno, Davide
    Angiolillo, Dominick J.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (07) : 588 - 598
  • [36] Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome
    Zhang, Lu
    Lu, Jun
    Dong, Weihua
    Tian, Huiping
    Feng, Weiyi
    You, Haisheng
    He, Hairong
    Ma, Jing
    Dong, Yalin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2017, 69 (03) : 147 - 155
  • [37] Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors
    Gil-Perez, Pablo
    Miguel Ruiz-Nodar, Juan
    Asuncion Esteve-Pastor, Maria
    Hortelano, Ignacio
    Villamia, Beatriz
    Vicente-Ibarra, Nuria
    Orenes-Pinero, Esteban
    Jesus Macias, Manuel
    Nunez-Martinez, Laura
    Carrillo, Luna
    Candela, Elena
    Veliz-Martinez, Andrea
    Lopez-Garcia, Cecilia
    Gabriel Martinez-Martinez, Juan
    Miguel Rivera-Caravaca, Jose
    Marin, Francisco
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 184
  • [38] Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes
    Wijeyeratne, Yanushi Dullewe
    Joshi, Rashi
    Heptinstall, Stan
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (03) : 257 - 269
  • [39] Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint
    Kubica, Jacek
    Adamski, Piotr
    Gajda, Robert
    Kubica, Aldona
    Ostrowska, Malgorzata
    Casu, Gavino
    Gorog, Diana A.
    Gurbel, Paul A.
    Hajdukiewicz, Tomasz
    Jaguszewski, Milosz
    Jeong, Young-Hoon
    Kosobucka-Ozdoba, Agata
    Motovska, Zuzana
    Niezgoda, Piotr
    Piasecki, Maciej
    Podhajski, Przemyslaw
    Raggi, Paolo
    Rahimov, Uzeyir
    Siller-Matula, Jolanta M.
    Skonieczny, Grzegorz
    Szarpak, Lukasz
    Szymanski, Pawel
    Tantry, Udaya
    Navarese, Eliano P.
    CARDIOLOGY JOURNAL, 2025, 32 (01) : 83 - 89
  • [40] Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients
    Azzahhafi, Jaouad
    van den Broek, Wout W. A.
    Yin, Dean R. P. P. Chan Pin
    van der Sangen, Niels M. R.
    Sivanesan, Shabiga
    Bofarid, Salahodin
    Peper, Joyce
    Claassens, Daniel M. F.
    Janssen, Paul W. A.
    Harmsze, Ankie M.
    Walhout, Ronald J.
    Gin, Melvyn Tjon Joe
    Nicastia, Deborah M.
    Langerveld, Jorina
    Vlachojannis, Georgios J.
    van Bommel, Rutger J.
    Appelman, Yolande
    van Schaik, Ron H. N.
    Henriques, Jose P. S.
    Kikkert, Wouter J.
    ten Berg, Jurrien M.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (17) : 1996 - 2007